JP2022539152A5 - - Google Patents

Info

Publication number
JP2022539152A5
JP2022539152A5 JP2021577411A JP2021577411A JP2022539152A5 JP 2022539152 A5 JP2022539152 A5 JP 2022539152A5 JP 2021577411 A JP2021577411 A JP 2021577411A JP 2021577411 A JP2021577411 A JP 2021577411A JP 2022539152 A5 JP2022539152 A5 JP 2022539152A5
Authority
JP
Japan
Prior art keywords
disease
parkinson
pharmaceutical composition
disorders
cognitive impairment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021577411A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022539152A (ja
JP7510444B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2020/068183 external-priority patent/WO2021001288A1/en
Publication of JP2022539152A publication Critical patent/JP2022539152A/ja
Publication of JP2022539152A5 publication Critical patent/JP2022539152A5/ja
Application granted granted Critical
Publication of JP7510444B2 publication Critical patent/JP7510444B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021577411A 2019-07-01 2020-06-29 Ｄ１ポジティブアロステリックモジュレーターとしての置換テトラヒドロイソキノリン誘導体 Active JP7510444B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19183643.6 2019-07-01
EP19183643 2019-07-01
PCT/EP2020/068183 WO2021001288A1 (en) 2019-07-01 2020-06-29 A substituted tetrahydroisoquinoline derivative as a d1 positive allosteric modulator

Publications (3)

Publication Number Publication Date
JP2022539152A JP2022539152A (ja) 2022-09-07
JP2022539152A5 true JP2022539152A5 (https=) 2023-06-30
JP7510444B2 JP7510444B2 (ja) 2024-07-03

Family

ID=67137843

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021577411A Active JP7510444B2 (ja) 2019-07-01 2020-06-29 Ｄ１ポジティブアロステリックモジュレーターとしての置換テトラヒドロイソキノリン誘導体

Country Status (23)

Country Link
US (1) US20220259179A1 (https=)
EP (1) EP3993794A1 (https=)
JP (1) JP7510444B2 (https=)
KR (1) KR20220029686A (https=)
CN (2) CN117700395A (https=)
AR (1) AR119318A1 (https=)
AU (1) AU2020299953B2 (https=)
BR (1) BR112021022378A2 (https=)
CA (1) CA3139571A1 (https=)
CL (1) CL2021002946A1 (https=)
CO (1) CO2021018155A2 (https=)
EC (1) ECSP21093559A (https=)
IL (2) IL289314B2 (https=)
MA (1) MA56440A (https=)
MX (2) MX2021015873A (https=)
MY (1) MY210361A (https=)
PE (1) PE20221020A1 (https=)
PH (1) PH12021552825A1 (https=)
SA (1) SA521431279B1 (https=)
SG (1) SG11202112537YA (https=)
TW (2) TWI875776B (https=)
WO (1) WO2021001288A1 (https=)
ZA (1) ZA202109193B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2976784T3 (es) 2020-10-07 2024-08-08 Lilly Co Eli Derivados de fenil-3,4-dihidroisoquinolin-2(1H)-il-etan-1-ona como moduladores alostéricos positivos del receptor de dopamina D1
US20240083925A1 (en) 2020-12-18 2024-03-14 UCB Biopharma SRL Prodrugs of 2-(3,5-Dichloro-1-methyl-indazol-4-yl)-1-[(1S,3R)-3-(hydroxymethyl)-5-(1-hydroxy-1-methyl-ethyl)-1-methyl-3,4-dihydro-1H-isoquinolin-2-yl]ethanone
JP7798891B2 (ja) 2020-12-18 2026-01-14 ユーシービー バイオファルマ エスアールエル Ｄ１陽性アロステリック調節因子としての置換テトラヒドロイソキノリン誘導体
WO2022129267A1 (en) * 2020-12-18 2022-06-23 UCB Biopharma SRL Amorphous solid dispersions
EP4304577A1 (en) * 2021-03-09 2024-01-17 Eli Lilly And Co. Use of mevidalen and other d1 positive allosteric modulators for slowing of parkinson's disease progression
WO2026022198A1 (en) 2024-07-25 2026-01-29 UCB Biopharma SRL Process for the preparation of 2-(3,5-dichloro-1-methyl-indazol-4-yl)-1-[(1 s,3 r)-3-(hydroxymethyl)-5-(1-hydroxy-1-methyl-ethyl)-1-methyl-3,4-dihydro-1 h-isoquinolin-2-yl]ethanone monohydrate

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2679735A1 (en) 2007-03-01 2008-09-12 Janssen Pharmaceutica N.V. Tetrahydroisoquinoline compounds as modulators of the histamine h3 receptor
KR101284796B1 (ko) 2011-10-05 2013-07-10 (주)포인트엔지니어링 캔 패지키 타입의 광 디바이스 제조 방법 및 이에 의해 제조된 광 디바이스
JO3316B1 (ar) * 2013-05-30 2019-03-13 Lilly Co Eli مركبات 3، 4-داي هيدرو أيزو كوينولين -2(1h)-يل
WO2016055479A1 (en) 2014-10-08 2016-04-14 Ucb Biopharma Sprl Tetrahydroisoquinoline derivatives
CN108884050B (zh) * 2016-04-13 2022-07-05 Ucb生物制药私人有限公司 四氢异喹啉衍生物
TWI725408B (zh) 2018-04-20 2021-04-21 美商美國禮來大藥廠 多巴胺d1受體正向異位調節劑

Similar Documents

Publication Publication Date Title
JP2022539152A5 (https=)
AU2019213454B2 (en) 7,8-dihydoxyflavone and 7,8-substituted flavone derivatives, compositions, and methods related thereto
ES2261234T3 (es) Metabolitos de bupropion y metodos de sintesis y uso.
JP2019059760A5 (https=)
NI201100100A (es) Moduladores de aril metil benzoquinazolinona alostéricos positivos del receptor m1.
JP2014517050A5 (https=)
JP2012530779A5 (https=)
JP2009511568A5 (https=)
JP2012508734A5 (https=)
JP2005508872A5 (https=)
JP2010513250A5 (https=)
JP2016537432A5 (https=)
JP2001523716A5 (https=)
JP2022537994A5 (https=)
JPWO2021153665A5 (https=)
CO6290669A2 (es) Usos terapeuticos de compuestos que tiene afinidad con el transportador de serotonina los receptores de serotonina y transportador de noraadrenalina
JP2019535715A5 (https=)
JP2018530612A5 (https=)
JP2021512086A5 (https=)
FI4263517T3 (fi) Substituoitu tetrahydroisokinoliinijohdannainen d1-positiivisena allosteerisenä modulaattorina
RU2022101512A (ru) Замещенное производное тетрагидроизохинолина, как позитивный аллостерический модулятор d1
JP2024511053A5 (https=)
JP2022548859A5 (https=)
RU2022101513A (ru) Замещенное производное тетрагидроизохинолина как позитивный аллостерический модулятор d1
JP2009501205A (ja) 精神病治療用組成物